Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma
- 21 August 2008
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 159 (3), 606-614
- https://doi.org/10.1111/j.1365-2133.2008.08709.x
Abstract
Background Patients with metastatic skin disease in malignant melanoma are difficult to treat, with unresectable lesions proving the biggest challenge. We have recently published data showing a significant clinical response in patients with multiple in-transit melanoma metastases treated with a combination of topical imiquimod and intralesional interleukin (IL)-2. Here we report the results of immunological analysis with the aim of highlighting correlations with our clinical findings. Objectives To investigate the systemic effects of our localized combination treatment in patients with accessible metastases of melanoma, and to correlate this with their clinical responses. Methods The peripheral blood mononuclear cells of patients were collected at various time points throughout the treatment. Using antibodies to T-cell subsets we measured the changes in cell populations, and along with polyclonal stimulation, changes in cytokine production from these cells over a treatment course. Results We report an increase in the mean CD4/CD8 ratio from 2·78 to 3·54 with treatment (P < 0·01), and a rise in the percentage of CD25+ cells in the CD4+ population from 14·52% to 38·56%. Furthermore, staining with activation and T-regulatory markers showed that the majority of this population is activated T cells. Cytokine analysis on polyclonally stimulated peripheral blood mononuclear cells showed an increase in the ability of cells to produce interferon (IFN)-γ over the treatment course, with an initial rise in the IFN-γ/IL-5 ratio in five of six patients. Conclusions The results of this study provide evidence that, in the majority of patients with in-transit metastases of melanoma, therapy with a combination of topical imiquimod and intralesional IL-2 induces a systemic immunological effect by reversing some of changes noted in patients with malignant disease.Keywords
This publication has 35 references indexed in Scilit:
- Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanomaBritish Journal of Dermatology, 2007
- In vivo peripheral expansion of naive CD4+CD25highFoxP3+ regulatory T cells in patients with multiple myelomaBlood, 2006
- Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Activated CD4+ CD25+ T cells suppress antigen‐specific CD4+ and CD8+ T cells but induce a suppressive phenotype only in CD4+ T cellsImmunology, 2005
- Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3‐expressing lymphocytes into the skin following treatment with the TLR7‐agonist imiquimodJournal of Cutaneous Pathology, 2005
- Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humansHuman Immunology, 2005
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB10401+ Patients With Renal Cell Carcinoma or MelanomaThe Journal of Experimental Medicine, 2002
- Regression in basal cell carcinoma: an immunohistochemical analysisBritish Journal of Dermatology, 1994
- Effects of dietary zinc on melanoma growth and experimental metastasisCancer Letters, 1983